Wang Jianglin, Zhou Lingyun, Yin Wenjun, Li Daiyang, Hu Can, Zuo Xiaocong
Department of Pharmacy, Third Xiangya Hospital, Central South University, Changsha 410013.
Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 Oct 28;45(10):1193-1198. doi: 10.11817/j.issn.1672-7347.2020.190191.
Contrast-induced acute kidney injury (CI-AKI) is the third cause of hospital-acquired AKI, and existing clinical prevention and treatment measures such as hydration therapy and/or administration of antioxidants N-acetylcysteine treatment and other treatments still show little effect on the prevention and treatment of CI-AKI. This study aims to explore the effect of Danhong injection on prevention of CI-AKI.
A total of 12 867 patients, who received coronary angiography, percutaneous coronary intervention, enhanced CT or vascular intervention in a tertiary hospital, were enrolled for this study. Among them, 423 in the treatment group received intravenous drip of Danhong injection, and 12 444 in the control group received routine medicine. Propensity score matching was conducted to balance confounding factors between the 2 groups and then the prevention effect of Danhong injection on CI-AKI was compared between them.
A total of 423 pairs of patients were matched successfully. The incidence of CI-AKI in the non-Danhong control group was higher than that in the Danhong treatment group (5.7% vs 2.4%). The difference between the 2 groups was statistically significant (<0.05). CI-AKI occurred maily in the Stage 1 in both the non-Danhong control group and the Danhong treatment group. The number of patients with Stage 1 of AKI in the control group was more than that in the treatment group, and the difference was statistically significant (<0.05). The incidence of AKI in Stage 2 and Stage 3 was less in both groups, and the difference was not statistically significant (>0.05).
The results of this study support the use of Danhong injection in the prevention of the Stage 1 of CI-AKI.
对比剂诱导的急性肾损伤（CI-AKI）是医院获得性急性肾损伤的第三大病因，而现有的临床预防和治疗措施，如水化疗法和/或给予抗氧化剂N-乙酰半胱氨酸治疗等，对CI-AKI的防治效果仍欠佳。本研究旨在探讨丹红注射液对预防CI-AKI的作用。
选取在某三级医院接受冠状动脉造影、经皮冠状动脉介入治疗、增强CT或血管介入治疗的12867例患者纳入本研究。其中，治疗组423例接受丹红注射液静脉滴注，对照组12444例接受常规药物治疗。进行倾向评分匹配以平衡两组间的混杂因素，然后比较两组间丹红注射液对CI-AKI的预防效果。
共成功匹配423对患者。非丹红对照组CI-AKI的发生率高于丹红治疗组（5.7%对2.4%）。两组间差异有统计学意义（<0.05）。非丹红对照组和丹红治疗组中CI-AKI主要发生在1期。对照组急性肾损伤1期患者数量多于治疗组，差异有统计学意义（<0.05）。两组中2期和3期急性肾损伤的发生率均较低，差异无统计学意义（>0.05）。
本研究结果支持丹红注射液用于预防CI-AKI的1期。
